Sirtratumab vedotin
Based on 1 Customer Validation
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 97.38%
- CAS No.: 1824663-83-3
-
Stockage:Shipping with dry ice
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P99681
Labetuzumab govitecanAnti-CEACAM5 ADC -
HY-141606
Anetumab ravtansineTubulin ADC -
HY-P99542
Tusamitamab ravtansineADC -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-141601
Telisotuzumab vedotinAnti-c-MET ADC -
HY-P99813
Patritumab deruxtecanHER3-Directed ADC -
HY-P99107A
Brentuximab vedotin (solution)ADC -
HY-152963
Tisotumab vedotinAntibody-Drug Conjugate -
HY-132253
Polatuzumab vedotinMicrotubule Inhibitor -
HY-132253A
Polatuzumab vedotin (solution)Microtubule Inhibitor -
HY-141604
Glembatumumab vedotinGPNMB ADC -
HY-141598
Datopotamab deruxtecan (solution)TROP2-Targeted ADC
Activité biologique
Description
In Vitro
Sirtratumab vedotin (ASG15-ME) shows high-affinity binding to SLITRK6 expressed on SW780 cells with a Kd of 0.018 nM[1].
Sirtratumab vedotin (10 μg/mL; 1 h) internalizes after binding to SLITRK6[1].
Sirtratumab vedotin (120 h) inhibits CHP-212 cell survival with an IC50 of 0.99 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CHP-212 and IGR-OV1 cells
-
Concentration:
-
Incubation Time:120 h
-
Result:Showed a dose-dependent inhibition of CHP-212 cell survival with an IC50 of 0.99 nM. Had no effect on IGR-OV1 cells (SLITRK6 negative) when applied at the same concentrations.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID mice, RT4 xenograft model[1]
-
Dosage:5 mg/kg
-
Administration:Intravenous injection, single dose
-
Result:Caused significant inhibition.
-
Animal Model:SCID mice, AG-B7 and AG-B8 xenograft model[1]
-
Dosage:0.25 and 0.5 mg/kg
-
Administration:Intravenous injection, 2x per week for 2 or 3 weeks
-
Result:Significantly reduced tumor volume.
-
Animal Model:SCID mice, the lung xenograft model NCI-H322M[1]
-
Dosage:3 mg/kg
-
Administration:Intravenous injection, 2x per week for 3 weeks
-
Result:Was able to cause 99% tumor growth inhibition.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1824663-83-3
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Sirtratumab vedotin]
-
Synonyms
AGS15E; ASG-15ME; 1vcMMAE
-
Livraison
Shipping with dry ice.
-
Stockage
-80°C, protect from light
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sirtratumab vedotin Related Classifications
HY-P99595 Related Classifications
Powered by Bioz